Baroreflex Activation Therapy for Resistant Hypertension and Heart Failure-Reference-Cited by-同舟云学术

Baroreflex Activation Therapy for Resistant Hypertension and Heart Failure

Published:2020-02-07 Issue:2 Volume:13 Page:83-87
ISSN:1758-390X
Container-title:US Cardiology Review
language:en
Short-container-title:

Author:

Dyrvig Kristensen Anna Meta¹,Pareek Manan²,Olsen Michael Hecht³,Bhatt Deepak L⁴,

Affiliation:

1. Department of Cardiology, North Zealand Hospital, Hilleroed, Denmark

2. Department of Cardiology, North Zealand Hospital, Hilleroed, Denmark; Brigham and Women’s Hospital Heart and Vascular Center, Harvard Medical School, Boston, MA

3. Cardiology Section, Department of Internal Medicine, Holbaek Hospital, Holbaek, Denmark

4. Brigham and Women’s Hospital Heart and Vascular Center, Harvard Medical School, Boston, MA

Abstract

Hypertension and heart failure are important contributors to global morbidity and mortality. Despite therapeutic lifestyle and pharmacological measures, a significant proportion of people with hypertension do not reach treatment targets. Patients with resistant or poorly controlled hypertension are at significantly increased risk of cardiovascular events, including heart failure. Since dysfunction of the sympathetic nervous system appears to play a key role in the development and progression of both hypertension and heart failure, these patients may benefit from treatment modalities aimed at reducing sympathetic function. The purpose of this paper is to provide an overview of baroreflex activation therapy as a potential treatment strategy in patients with resistant hypertension or heart failure.

Publisher

Radcliffe Group Ltd

Subject

Cardiology and Cardiovascular Medicine

Reference64 articles.

1. 1. Olsen MH, Angell SY, Asma S, et al. A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension. Lancet 2016;388:2665-2712. https://doi.org/10.1016/S0140-6736(16)31134-5; PMID: 27671667.

2. 2. GBD 2017 Risk Factor Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018;392:1923-94. https://doi.org/10.1016/S0140-6736(18)32225-6; PMID: 30496105.

3. 3. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19.1 million participants. Lancet 2017;389:37-55. https://doi.org/10.1016/S0140-6736(16)31919-5; PMID: 27863813.

4. 4. Benjamin EJ, Virani SS, Callaway CW, et al. Heart disease and stroke statistics - 2018 Update: A Report from the American Heart Association. Circulation 2018;137:e67-e492. https://doi.org/10.1161/CIR.0000000000000573; PMID: 29386200.

5. 5. Daugherty SL, Powers JD, Magid DJ, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 2012;125:1635-42. https://doi.org/10.1161/CIRCULATIONAHA.111.068064; PMID: 22379110.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Device Therapies for Hypertension;Hypertension;2024

2. Neurogenic Hypertension, the Blood–Brain Barrier, and the Potential Role of Targeted Nanotherapeutics;International Journal of Molecular Sciences;2023-01-22